Shots:

• The P-III (NCT02524847) study involves assessing of Therakos + methoxsalene in 25 pediatric patients with aGvHD aged 1 yr to 21 yrs. @4-12 wks.
• The P-III study resulted in general response rates @4-12 wks. (74%- 48%-) with OR exceeding the target rates in mid-term study
• Therakos Immunotherapy is delivered using CELLEX system for the treatment of skin manifestations in CTCL used in almost 25 countries

Ref: PRNewsWire | Image: WSJ